Last reviewed · How we verify

NCT03761940: OSTaRa

Health Status of Women With Breast Cancer

Status unknown Last updated 6 May 2019
What this trial tests

trial testing EQ5D questionnaire and a demographic questionnaire in Women With Early Breast Cancer in 200 participants. Status unknown.

Timeline
14 March 2019
Primary endpoint
30 November 2019
30 November 2019

Quick facts

Lead sponsorUniversity College, London
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment200
Start date14 March 2019
Primary completion30 November 2019
Estimated completion30 November 2019
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University College, London

Who can join

18 and older, female only, with Women With Early Breast Cancer or Breast Conserving Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The quality-adjusted life-year (QALY) is the outcome measure of choice in England and Wales for National Institute for Health and Care Excellence (NICE). To be able to conduct a cost utility analysis, QALY data is required. This can either be collected within trial or published data can be used. In the United Kingdom (UK) there is no up to date QALY data for women with early breast cancer treated with surgery followed by radiotherapy. The OSTaRa Study aims to provide up to date QALY data for women in this cohort.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University College, London trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03761940.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing